Tourmaline Bio, Inc.
TRML
$15.10
-$0.64-4.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -72.89% | -73.80% | -87.09% | -- | -- |
| Total Depreciation and Amortization | 10.81% | 18.18% | 51.85% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -102.68% | -106.62% | -71.88% | -- | -- |
| Change in Net Operating Assets | 84.44% | -1,777.38% | -2,152.94% | -- | -- |
| Cash from Operations | -114.26% | -175.14% | -183.00% | -- | -- |
| Capital Expenditure | 43.75% | 83.93% | 98.17% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 111.10% | -5,087.06% | -- | -- | -- |
| Cash from Investing | 111.08% | -5,160.03% | -189,625.69% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.65% | 111,950.00% | 111,950.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 2,110.68% | -- | -- |
| Cash from Financing | -99.82% | 2.95% | 159.09% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -167.08% | -183.20% | -165.96% | -- | -- |